GDRX - Trevor Bezdek Schedule 13D (Amendment No. 2)

SC 13D/A 1 gdrx-trevorbezdekschedule1.htm SC 13D/A GDRX - Trevor Bezdek Schedule 13D (Amendment No. 2)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

GoodRx Holdings, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

38246G108

(CUSIP Number)

Trevor Bezdek

c/o GoodRx Holdings, Inc.

2701 Olympic Boulevard

Santa Monica, CA 90404

(855) 268-2822

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

June 7, 2024

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject

of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the

following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including

all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

_____________

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with

respect to the subject class of securities, and for any subsequent amendment containing information which would

alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose

of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of

the Act but shall be subject to all other provisions of the Act (however, see the Notes).


1	Names of Reporting Persons Trevor Bezdek
2	Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ]
3	SEC Use Only
4	Source of Funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ]
6	Citizenship or Place of Organization United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	Sole Voting Power 2,632,721
		8	Shared Voting Power 2,632,721
		9	Sole Dispositive Power 2,632,721
		10	Shared Dispositive Power 2,632,721
11	Aggregate Amount Beneficially Owned by Each Reporting Person 5,265,442
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ]
13	Percent of Class Represented by Amount in Row (11) 5.6%
14	Type of Reporting Person IN


CUSIP No. 38246G108	13D/A	Page 1 of 6 pages

EXPLANATORY NOTE

This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) amends and

supplements the statement on Schedule 13D filed with the Securities and Exchange Commission

on August 31, 2023 (as amended to date, the “Schedule 13D”) relating to the shares of Class A

Common Stock, par value $0.0001 per share (the “Class A Common Stock”), of GoodRx

Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used but not defined

herein shall have the meaning ascribed thereto in the Schedule 13D.

Item 4.Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

Gift Transactions

On June 7, 2024, the Reporting Person gifted 2,632,721 shares of Class A Common

Stock to the Reporting Person’s spouse.

On June 10, 2024, the Reporting Person gifted 2,632,721 shares of Class A Common

Stock to a grantor retained annuity trust (the “TB 2024 GRAT”) of which the Reporting Person

is the sole trustee and annuitant. Also on June 10, 2024, the Reporting Person’s spouse gifted

2,632,721 shares of Class A Common Stock to a grantor retained annuity trust (the “JB 2024

GRAT”), of which the Reporting Person’s spouse is the sole trustee and annuitant.

As a result of the foregoing transactions, the Reporting Person no longer has voting or

dispositive power over the Class A Common Stock held by the JB 2024 GRAT. The Reporting

Person does not exercise voting or dispositive power over the Class A Common Stock held of

record by the JB 2024 GRAT. The inclusion in this Amendment No. 2 of the Class A Common

Stock held of record by the JB 2024 GRAT and disclosure related thereto is not an admission or

acknowledgement that the Reporting Person beneficially owns such Class A Common Stock.

The Reporting Person disclaims beneficial ownership of the Class A Common Stock held by the

JB 2024 GRAT.

Rule 10b5-1 Trading Plans

On June 7, 2024, pursuant to the Board’s prior approval in accordance with the terms of

the Reporting Person’s Second Amended and Restated Employment Agreement, the Reporting

Person terminated the Trading Plan and entered into a modified Rule 10b5-1 Plan (the “TB 2024

GRAT Trading Plan”), pursuant to which the Reporting Person and the TB 2024 GRAT may

make periodic sales of up to 2,632,721 shares of Class A Common Stock plus an undeterminable

number of Class A Common Stock related to restricted stock units that have not yet vested. The

amount and timing of sales, if any, pursuant to the TB 2024 GRAT Trading Plan may vary and


CUSIP No. 38246G108	13D/A	Page 2 of 6 pages

will be determined based on the terms of the TB 2024 GRAT Trading Plan, market conditions,

share price and other factors.

Also on June 7, 2024 and further pursuant to the Board’s prior approval in accordance

with the terms of the Reporting Person’s Second Amended and Restated Employment

Agreement, the Reporting Person’s spouse entered into a new Rule 10b5-1 Plan (the “JB 2024

GRAT Trading Plan”), pursuant to which the JB 2024 GRAT may make periodic sales of up to

2,632,721 shares of Class A Common Stock. The amount and timing of sales, if any, pursuant to

the JB 2024 GRAT Trading Plan may vary and will be determined based on the terms of the JB

2024 GRAT Trading Plan, market conditions, share price and other factors.

The foregoing descriptions of the TB 2024 GRAT Trading Plan and the JB 2024 GRAT

Trading Plan do not purport to be complete and are qualified in their entirety by the full text of

such trading plans. A copy of each of the TB 2024 GRAT Trading Plan and the JB 2024 GRAT

Trading Plan is filed as an exhibit to this Schedule 13D, and incorporated herein by reference.

Item 5.Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated as follows:

(a) – (b)

•Amount beneficially owned: 5,265,442†

•Percent of Class: 5.6%†

•Number of shares the Reporting Person has:

oSole power to vote or direct the vote: 2,632,721

oShared power to vote: 2,632,721†

oSole power to dispose or direct the disposition of: 2,632,721

oShared power to dispose or direct the disposition of: 2,632,721†

The share amount reported herein consists of (i) 2,632,721 shares of Class A Common

Stock held by the TB 2024 GRAT and (ii) 2,632,721 shares of Class A Common Stock held by

the JB 2024 GRAT.†

The above percentage is based on 94,335,792 shares of Class A Common Stock

outstanding as of April 30, 2024, as disclosed in the Quarterly Report of the Issuer on Form 10-Q

filed with the Securities and Exchange Commission on May 9, 2024.


CUSIP No. 38246G108	13D/A	Page 3 of 6 pages

† The Reporting Person does not exercise voting or dispositive power over the Class A Common

Stock held of record by the JB 2024 GRAT. The inclusion in this Amendment No. 2 of the Class

A Common Stock held of record by the JB 2024 GRAT and disclosure related thereto is not an

admission or acknowledgement that the Reporting Person beneficially owns such Class A

Common Stock. The Reporting Person disclaims beneficial ownership of the Class A Common

Stock held by the JB 2024 GRAT.

(c)On June 1, 2024, the Reporting Person acquired 126,552 shares of Class A Common

Stock as a result of the vesting of RSUs, after the Issuer withheld 130,042 shares of Class

A Common Stock underlying Class B Common Stock from the Reporting Person to

satisfy tax withholding obligations. Except as described in this Amendment No. 2, in the

last 60 days, the Reporting Person has not effected any transactions with respect to the

Class A Common Stock.

(d)None.

(e)Not applicable.

Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to

Securities of the Issuer.

Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

Item 4 above summarizes certain provisions of the TB 2024 GRAT Trading Plan and the

JB 2024 GRAT Trading Plan and is incorporated herein by reference. A copy of each of the TB

2024 GRAT Trading Plan and the JB 2024 GRAT Trading Plan is attached as an exhibit to this

Schedule 13D, and incorporated herein by reference.

Item 7.Materials to be Filed as Exhibits.

Item 7 of the Schedule 13D is hereby amended and supplemented as follows:


Exhibit Number	Description
5	TB 2024 GRAT Trading Plan.
7	JB 2024 GRAT Trading Plan.


CUSIP No. 38246G108	13D/A	Page 4 of 6 pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the

information set forth in this statement is true, complete and correct.

Date: June 11, 2024


By:		/s/ Trevor Bezdek

Name:		Trevor Bezdek


CUSIP No. 38246G108	13D/A	Page 5 of 6 pages

Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.